AGN
$22M5mo
Argenica Therapeutics Limited
Neurology
Developing neuroprotective peptide ARG-007 for stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$5.0M
Dec 2025 4C
Runway
5moCRITICAL
Based on Dec 2025 4C
Market Cap
$22M
Burn Rate
$2.8M/qtr
Dec 2025 4C
Shares Outstanding
128M
Pipeline Assets
3
Latest Insight(1)
10 Feb 2026Half YearHalf Yearly Report and Accounts
Cash$5.0M·Burn$5.5M/q·OCF$-5.5M
3M Price
AGN.ASX$0.175-32.7% 3M
Low $0.140High $0.295
Pipeline Assets (3)
ARG-007traumatic brain injury
PreclinicalARG-007hypoxic ischaemic encephalopathy
PreclinicalARG-007acute ischaemic stroke
Phase 2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
2 approved drugs299 competitor trialsPhase 2+ · Non-ASX
Traumatic Brain Injury90 active trials
11 Ph422 Ph38 Ph2/342 Ph27 Ph1/PHASE2
Approved
Hypoxic Ischaemic Encephalopathy17 active trials
2 Ph43 Ph310 Ph22 Ph1/PHASE2
Acute Ischaemic Stroke192 active trials
34 Ph482 Ph319 Ph2/346 Ph211 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (4)· 2 upcoming · 2 past
ARG-007 Phase 2 SEANCON results at ESOC 2026 (Maastricht)
UpcomingConfirmedremoveMed7 May 2026
ARG-007 Phase 2b trial design announcement (stroke)
UpcomingExpectedarrow_upwardHigh31 Dec 2026
expand_more2 past catalysts
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(1)
No active trials